IL232890A0 - Immunogenic therapy for cancer - Google Patents

Immunogenic therapy for cancer

Info

Publication number
IL232890A0
IL232890A0 IL232890A IL23289014A IL232890A0 IL 232890 A0 IL232890 A0 IL 232890A0 IL 232890 A IL232890 A IL 232890A IL 23289014 A IL23289014 A IL 23289014A IL 232890 A0 IL232890 A0 IL 232890A0
Authority
IL
Israel
Prior art keywords
cancer
immunogenic treatment
immunogenic
treatment
Prior art date
Application number
IL232890A
Other languages
English (en)
Hebrew (he)
Original Assignee
Immodulon Therapeutics Ltd
Akle Charles
Mudan Satvinder
Grange John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd, Akle Charles, Mudan Satvinder, Grange John filed Critical Immodulon Therapeutics Ltd
Publication of IL232890A0 publication Critical patent/IL232890A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL232890A 2011-12-02 2014-05-29 Immunogenic therapy for cancer IL232890A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (1)

Publication Number Publication Date
IL232890A0 true IL232890A0 (en) 2014-07-31

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232890A IL232890A0 (en) 2011-12-02 2014-05-29 Immunogenic therapy for cancer

Country Status (15)

Country Link
US (4) US20140356397A1 (cg-RX-API-DMAC7.html)
EP (1) EP2785361B1 (cg-RX-API-DMAC7.html)
JP (1) JP6085611B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140097419A (cg-RX-API-DMAC7.html)
CN (1) CN104023733A (cg-RX-API-DMAC7.html)
AU (1) AU2012343536B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012880A2 (cg-RX-API-DMAC7.html)
CA (1) CA2857429A1 (cg-RX-API-DMAC7.html)
GB (1) GB201120779D0 (cg-RX-API-DMAC7.html)
IL (1) IL232890A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN00955A (cg-RX-API-DMAC7.html)
MX (1) MX2014006511A (cg-RX-API-DMAC7.html)
RU (1) RU2014121335A (cg-RX-API-DMAC7.html)
SG (1) SG11201402396XA (cg-RX-API-DMAC7.html)
WO (1) WO2013079980A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US11141216B2 (en) 2015-01-30 2021-10-12 Immunsys, Inc. Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
PL3319635T3 (pl) * 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
RU2018136347A (ru) * 2016-04-14 2020-05-14 Фелдрайх Каро Руиз Аб Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света
CA3058380A1 (en) 2017-03-28 2018-10-04 Emblation Limited Stenosis treatment
US11173325B2 (en) 2017-07-21 2021-11-16 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agent
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
MA54399A (fr) 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
US20230045616A1 (en) * 2019-12-27 2023-02-09 Nonprofit Organization North East Japan Study Group Cancer treatment method and medicine
EP4376945A1 (en) * 2021-07-27 2024-06-05 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
EP0556248B1 (en) * 1990-11-08 1997-06-25 University College London Mycobacterium as adjuvant for antigens
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
WO2000064476A2 (en) 1999-04-23 2000-11-02 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090297540A1 (en) 2005-10-21 2009-12-03 Andrew Mellor Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
US8557257B2 (en) * 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
US9114158B2 (en) * 2011-03-09 2015-08-25 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
WO2013114367A2 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
EP3092004A4 (en) 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
PL3319635T3 (pl) 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
CN112672758A (zh) 2018-06-25 2021-04-16 英摩杜伦治疗学公司 癌症治疗

Also Published As

Publication number Publication date
US20190224294A1 (en) 2019-07-25
RU2014121335A (ru) 2016-01-27
US20140356397A1 (en) 2014-12-04
BR112014012880A2 (pt) 2017-06-13
MX2014006511A (es) 2014-12-05
IN2014MN00955A (cg-RX-API-DMAC7.html) 2015-04-24
AU2012343536A1 (en) 2014-06-05
WO2013079980A1 (en) 2013-06-06
CN104023733A (zh) 2014-09-03
EP2785361A1 (en) 2014-10-08
JP6085611B2 (ja) 2017-02-22
AU2012343536B2 (en) 2017-08-24
JP2014533743A (ja) 2014-12-15
GB201120779D0 (en) 2012-01-11
US11318193B2 (en) 2022-05-03
US11554166B2 (en) 2023-01-17
EP2785361B1 (en) 2018-11-28
US20230149525A1 (en) 2023-05-18
NZ624994A (en) 2016-10-28
CA2857429A1 (en) 2013-06-06
US20200338181A1 (en) 2020-10-29
SG11201402396XA (en) 2014-10-30
KR20140097419A (ko) 2014-08-06

Similar Documents

Publication Publication Date Title
IL232890A0 (en) Immunogenic therapy for cancer
IL232530A0 (en) Combined cancer treatment
PH12014500248A1 (en) Treatment of breast cancer
EP2760452A4 (en) METHODS OF TREATING CANCER
SG10201508495VA (en) Combination treatment of cancer
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
ZA201307036B (en) Treatment of solid tumours
IL228430A0 (en) Cancer treatment
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
EP2903644A4 (en) TREATMENT OF CANCER
HUE056646T2 (hu) Adjuváns rákkezelés eljárása
GB201217892D0 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
IL231987A0 (en) Medical combination for cancer treatment
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
AU2012905667A0 (en) Vaccines for treatment of cancer
GB201208296D0 (en) Treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
IL232266A0 (en) Cancer treatment methods
GB201017356D0 (en) Combination treatment of cancer